0.51
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BioPharmX Corporation | BPMX | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 0.51 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.51 | 0.51 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.51 | USD |
BioPharmX Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 9.32M | 18.28M | - | $ - | $ - | -0.80 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 1.09M | $ - | 0.00% | - | - |
BioPharmX News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BPMX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Year | 0.74 | 1.09 | 0.25 | 0.4975372 | 2,224,690 | -0.23 | -31.08% |
| 3 Years | 3.375 | 9.3775 | 0.1965 | 4.22 | 4,373,134 | -2.87 | -84.89% |
| 5 Years | 40.50 | 46.00 | 0.1965 | 5.04 | 2,881,142 | -39.99 | -98.74% |
BioPharmX Description
| BioPharmX Corp specialty pharmaceutical company engaged in utilizing its proprietary drug delivery technologies to develop and commercialize novel prescription products that address large markets in dermatology. Its objective is to develop products that treat health or age-related conditions that are not presently being addressed or treated with drug therapies or drug delivery approaches that are sub-optimal. The company has developed its product portfolio using its proprietary drug delivery technologies, including delivery mechanisms for antibiotics, biologic materials, and molecular iodine. Its products include VI2OLET iodine dietary supplement, two clinical-stage product candidates, BPX01 and BPX03 and one development-stage product candidate, BPX02. |
